Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.
AbbVie is slashing 178 jobs from the company’s Stemcentrx subsidiary in South San Francisco.
AbbVie’s Rova-T Sees Another Failure
Acquisitions, Advanced small-cell lung cancer, Antibody Drug Conjugates (ADC), Blockbusters, Cancer Cells, Clinical Trials, Data Monitoring Committee (DMC), Delta-like protein 3 (DLL3), Glioblastoma Multiforme (GBM), R&D, Small cell lung cancer, Stocks, Tumor CellsAbbVie halted a Phase III trial evaluating rovalpituzumab tesirine as a second-line therapy for advanced small-cell lung cancer after an Independent Data Monitoring Committee called for the stoppage due to shorter overall survival in the Rova-T arm.
Companies Continue to Take Aim at Glioblastoma, a Cancer Highlighted by the Death of Sen. John McCain
Antigens, Brain Cancer, China Food and Drug Administration, Clinical Trials, Clinical Trials, Gene Therapy, Glioblastoma Multiforme (GBM), Immunotherapies, National Institute of Health, Proteasome Inhibitors, R&D, Rare Diseases, Small MoleculesCiting the National Institutes of Health (NIH), CNN reported there are 274 glioblastoma multiforme studies underway or recruiting across the United States.
Bexion Pharmaceuticals and the drugmaker’s investigational cancer treatment BXQ-350 is receiving lots of mainstream media coverage as a potential game changer.
The U.S. Food and Drug Administration granted orphan drug designation to PharmAbcine Inc.’s leading clinical compound TTAC-0001 for the treatment of glioblastoma multiforme.
